Grifols SA GRIFOLS ORD SHS CLASS .../ ES0171996087 /
| 2024-11-15 11:09:03 AM | Chg. +0.10 | Volume | Bid2024-11-15 | Ask2024-11-15 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.25EUR | +0.94% | 5,928 Turnover: 65,729.78 |
10.92Bid Size: 3,000 | 11.41Ask Size: 3,000 | 9.5 bill.EUR | - | 123.72 |
GlobeNewswire
07-29
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strength...
GlobeNewswire
07-01
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
GlobeNewswire
06-18
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
GlobeNewswire
06-17
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...
GlobeNewswire
04-18
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...
GlobeNewswire
04-04
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...
GlobeNewswire
2023-11-15
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...
